Health care stocks were edging higher premarket Thursday, with the iShares Biotechnology ETF (IBB) and The Health Care Select Sector SPDR Fund (XLV) up 0.6%.
Neumora Therapeutics (NMRA) shares were down more than 82% after the company said that the phase 3 KOASTAL-1 study of navacaprant in treating major depressive disorder failed to meet its primary endpoint.
Hutchmed (China) (HCM) shares were up more than 5% after the company said overnight that the China National Medical Products Administration has accepted and granted priority review to its New Drug Application for the combination of Orpathys and Tagrisso for the treatment of patients with a specific type of non-small cell lung cancer.
ANI Pharmaceuticals (ANIP) shares were up over 4% after the company said it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.